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C O M M E N T A R Y
Pharmacogenomic testing
Enhancing personalized medication use for patients
Catrina M. Loucks MSc PhD Gabriella Groeneweg MA Carl Roy David K. Lee Michael J. Rieder MD PhD  
Denis Lebel MSc FCSHP Shinya Ito MD FRCPC Colin J. Ross MSc PhD Bruce C. Carleton PharmD FCP FISPE 
A dverse drug reactions (ADRs) are an important clinical problem in modern medicine, sometimes resulting in debilitating and lethal consequences 
for patients. The burden of ADRs in Canada is under-
emphasized owing to most ADRs going unreported.1 
However, a 1998 study suggests that ADRs are between 
the fourth and sixth leading cause of death of hospital-
ized patients in the United States.2 Genomic factors play a 
key role in drug response and contribute substantially to 
the risk of drug-induced harm. Pharmacogenomics—the 
determination of the genomic predisposition to a certain 
response to medication—is a key component in under-
standing how to use medication in a safer and more 
effective manner. Pharmacogenomic testing allows for 
the detection of genomic factors linked to differences in 
drug response before treatment, ensuring that the ben-
efit of a medication is maximized without the unintended 
consequences of ADRs. While medication use in clinical 
practice is already personalized by considering clinical 
factors that contribute to variable drug responses, phar-
macogenomic testing can explain why some patients 
experience unusual responses to medication and further 
enhances personalized medication use.
The Canadian Pharmacogenomics Network for Drug 
Safety (CPNDS),3 a group focused on incorporating 
pharmacogenomics into clinical practice, has identi-
fied genomic factors responsible for a number of ADRs, 
including but not limited to codeine-induced death in 
breastfed infants,4,5 cisplatin-induced ototoxicity,6,7 and 
anthracycline-induced cardiotoxicity.8-10 To address 
these serious ADRs, pharmacogenomic tests have been 
developed to assess a given patient’s risk of experi-
encing an ADR. Clinical practice guidelines have also 
been created to help clinicians develop better personal-
ized therapy plans based on genomic risk.11-13 As more 
genomic risk factors for ADRs are identified, pharma-
cogenomic testing can be optimized to provide better 
risk-benefit profiling for each patient.
The CPNDS and childhood cancer treatment
The CPNDS has worked to incorporate pharmacoge-
nomic testing into childhood cancer treatment deci-
sions to reduce the risk of developing ADRs such as 
anthracycline-induced cardiotoxicity. Anthracyclines, 
the most frequently used chemotherapeutic drug in 
Canada, can cause cardiac dysfunction leading to con-
gestive heart failure in up to 20% of treated children.13 
Based on clinical factors alone, the predicted risk of 
experiencing this cardiac dysfunction (cardiotoxicity) 
generally falls in the range of a few percent to an almost 
100% chance. Incorporating pharmacogenomic testing 
helps to better determine a patient’s specific risk before 
treatment initiation. For instance, in 2 patients with the 
same diagnosis, one patient’s genomic risk of serious 
cardiotoxicity might be below 20%, whereas the second 
patient’s risk might be greater than 80%. Importantly, 
this ability to quantify pharmacogenomic risk provides 
a vehicle for patients and their families to dictate the 
level of risk they are comfortable with, in the paradigm 
of benefit-risk decision making in their cancer treat-
ment. This exemplifies patient-oriented care, where an 
estimated risk of serious drug-induced cardiotoxicity of 
less than 20% might be acceptable given the consider-
able mortality that accompanies many cancer diagno-
ses. However, a predicted risk of drug-induced harm of 
more than 80% should require discussion of viable alter-
natives and pre-emptive preventive therapy. Together, 
this allows for better profiling for each patient to make 
informed treatment decisions.
Changes to drug labels
The CPNDS is not the only group focused on finding 
drug safety solutions through pharmacogenomics. Both 
the US Clinical Pharmacogenetics Implementation 
Consortium14 and the Dutch Pharmacogenetics Working 
Group15 also promote the use of pharmacogenomic infor-
mation to enhance clinical decision making. The CPNDS 
found that the use of codeine for postpartum pain man-
agement in mothers with an extra copy of the cyto-
chrome P450 2D6 isozyme gene (CYP2D6) can be lethal 
for their breastfed infants.5 These findings have led to 
warnings and drug label changes by Health Canada, the 
US Food and Drug Administration (FDA), the European 
Medicines Agency, and the Pharmaceuticals and Medical 
Devices Agency in Japan. Importantly, this research led 
to changes in the use of codeine worldwide.11,15,16
Pharmacogenomic information to inform clinical 
practice is included on more than 750 drug labels world-
wide (https://www.pharmgkb.org/labels), a number 
that continues to rise as more pharmacogenomic dis-
coveries are made. Currently, the FDA provides phar-
macogenomic information on 335 drug labels, while 
Health Canada has been slower to incorporate such 
information (included in 105 labels). Given that drugs 
are used across all medical disciplines, pharmacoge-
nomics should be the highest of priorities in both patient 
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care advancement and federal investment in research. 
To this end, the FDA facilitates the application of phar-
macogenomics in clinical practice through initiatives 
driven by the Genomics and Targeted Therapy Group. A 
similar approach could be adopted by Health Canada as 
a first step toward improving awareness of pharmacoge-
nomic information to guide prescribing decisions for 
Canadian physicians.
Integrating pharmacogenomic testing into 
clinical practice
Clinicians who want to integrate pharmacogenomic test-
ing into their practices face considerable challenges that 
limit access. We propose an approach where pharma-
cogenomic testing is conducted only when a particular 
drug is being considered for treatment. The inclusion of 
only pharmacogenomic variants with clinical relevance, 
such as those appearing on drug labels or in pharma-
cogenomic clinical practice guidelines, or those repli-
cated in at least 3 independent populations with strong 
associations (ie, odds ratios ≥ 3), allows for immediate 
and evidence-based application to prescribing decisions. 
Another possible avenue to improve accessibility is a 
screening approach where comprehensive pharmacoge-
nomic information is collected and readily available for 
future prescribing decisions. This is an attractive strat-
egy given the ever increasing affordability of genetic test-
ing, and likely represents the future of pharmacogenomic 
testing,17 but has obstacles for successful implementation. 
A pharmacogenomic screening approach must adhere 
to criteria outlined by Wilson and Jungner18 that have 
been adapted to guide genomic screening approaches,19 
with particular emphasis placed on providing strong evi-
dence for improved patient outcomes and cost effective-
ness through formal program evaluations. Furthermore, 
deciding which variants should be reported and main-
taining an updated list of variants with clinical relevance 
will require ongoing resources and management of the 
genomic data collected from screening.
Limitations of the health care system
Perceived resource constraints within the Canadian 
health care system might threaten adoption of phar-
macogenomic testing. We therefore propose prioritiz-
ing serious ADRs where delays in access to tests put 
patients at risk of devastating consequences that also 
represent substantial cost burdens on the health care 
system. Pharmacogenomic testing for serious ADRs also 
holds the most promise for cost effectiveness. We have 
shown that cost savings associated with the preven-
tion of one such ADR, anthracycline-induced cardio-
toxicity, are predicted to outweigh the costs of testing.20 
Specifically, severe cases of anthracycline-induced car-
diotoxicity cost more than $1 million owing to the need 
for heart transplants,20 and incorporation of pharma-
cogenomic testing is estimated to save $495 per patient, 
representing a 5.7% reduction in costs associated with 
anthracycline-based cancer treatment.20
Several parameters must be optimized to improve 
access for our proposed approach to pharmacogenomic 
testing, including turnaround time for return of results; 
integration of sample collection and return of results into 
linic flow; and availability of pharmacogenomics training. 
By prioritizing serious ADRs, such as those encountered 
in childhood cancer treatment, the CPNDS is gaining 
understanding of how best to deliver pharmacogenomic 
testing to suit the needs of physicians, patients, and 
families, while also assessing the effect of such testing 
on the Canadian health care system by formally evaluat-
ing cost effectiveness. Importantly, lessons learned from 
these experiences will help family physicians incorpo-
rate pharmacogenomic testing for additional serious 
ADRs in the future. In particular, clinically relevant phar-
macogenomic information informs the risk of experi-
encing the many serious ADRs encountered as a result 
of analgesics (eg, codeine- or tramadol-induced central 
nervous system depression or death), antibiotics (eg, 
rifampin-isoniazid-pyrazinamide–induced liver injury), 
and psychotropic medications (eg, carbamazepine- or 
phenytoin-induced skin reactions) that are commonly 
prescribed by family physicians. Given that these seri-
ous ADRs are typically rare, ordering pharmacogenomic 
testing will allow family physicians to continue prescrib-
ing highly effective drugs with well understood safety 
profiles in patients determined to be at low risk of expe-
riencing ADRs, while choosing alternative drugs and 
avoiding potential harm in patients at high risk.
Conclusion
Ultimately, increasing accessibility to pharmacogenomic 
tests means better profiling risks of therapy before ther-
apy begins and provides the potential to drastically affect 
the use of medication by making it safer, more effective, 
and personalized. It is an ethical responsibility for all of 
us—clinicians, hospital administrators, and policy mak-
ers—to provide access to this service to all Canadian 
families to help prevent serious ADRs when battling dis-
eases and illnesses that require medication.   
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